Skip To Main Content
Richard J. Chang on Muck Rack

Richard J. Chang

Verified
New York
As seen in: Fund Fire, LinkedIn, CNN, MSN, Forbes, Flipboard, Forbes México, Forbes Brasil, Forbes España, Forbes Japan, Forbes Middle East and
Reporter @FundFire @FT | Former @LinkedInNews @Forbes @CNNPolitics @dailyorange @metrowestdaily | Tips ✉️richard.chang@ft.com

Get in touch with Richard J.

Contact Richard J., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

I’m 63 and a Retired Government Worker With a $95k-a-year Pension and $100K in Savings. But I Owe $240K on My Home.

|
By Richard J. Chang Verified
| cfp.net
The Finance Files (LinkedIn) Financial planning and analysis roles are some of the fastest-growing jobs, but the wealth management and consulting industry has faced challenges trying to build a pipeline of young finance professionals. Jason Gudenius, Managing Director of Workforce at CFP Board, says, “Firms should look beyond experienced hires and invest in recent graduates and career changers.” The Finance Files (LinkedIn) Richard J. Chang May 9, 2025
Open in Who Shared Issue with article?

Los Hochschild, traen su colección privada de arte a Madrid

|
By Gabriella Mateos, Brett Knight Verified, Richard J. Chang Verified
| Forbes España Verified
Eduardo Hochschild (Lima, 61) es un ingeniero, empresario y filántropo peruano, dueño del Grupo Hochschild, que lidera en sectores como la minería y el cemento. Como filántropo y uno de los hombres más poderosos del país, ha impulsado iniciativas educativas importantes en Perú, como Tecsup y la Universidad de Ingeniería y Tecnología (UTEC). Junto a su mujer, Mariana Correa, forma uno de los matrimonios más ricos del país latinoamericano y son famosos por su amor al arte.
Open in Who Shared Issue with article?

Professor got nothing from the $2.8b sale of his molecule, and that's okay

|
By Mark Whittaker, Shivaune Field, Kerry Dolan Verified, Richard J. Chang Verified
| Forbes Australia Verified
Published on October 17, 2024 Professor Andrew Wilks would have loved to have still had skin in the momelotinib game. He might have got nothing when GSK bought the cancer-fighting molecule – which gets its name from “molecule Melbourne” – for $2.8 billion in 2023, but it has been good to him, nevertheless. After a quarter century momelotinib was approved by the US FDA as a bone-marrow cancer treatment last year and is already saving lives.
Open in Who Shared Issue with article?
See all 131 articles